Future progress in the treatment of childhood cancer is dependent upon the development of more efficacious and less toxic novel therapeutic agents. This proposal will detail the infrastructure and research objectives of the Children's Oncology Group (COG) Phasel/Pilot Consortium that has been developed to meet the new challenges of developing conventional and molecularly targeted drugs for pediatric cancers. The mission of the COG Phasel/Pilot Consortium is to identify and develop effective new agents for children and adolescents with cancer, through scientifically rational and efficient clinical and laboratory research. The new Consortium is comprised of COG institutions who, based on the results of an objective, peer-reviewed process, were found to have the best capability of accruing patients to phase l studies; the necessary infrastructure to carry out phase l and pilot studies including correlative studies; and the most qualified and experienced investigators in pediatric cancer drug development. The Consortium has been structured to have a highly efficient and productive process for the development and implementation of pediatric phase l and pilot studies. The Operations Center and Statistics and Data Center are closely integrated to provide efficient support of the administrative, regulatory compliance, financial management, study coordination, data acquisition, statistical science, quality assurance, and performance monitoring activities of the Consortium. The Consortium has indepth experience in developing a broad spectrum of new agents for children with cancer, including cytotoxic drugs, biologic agents, modulating agents, and signal transduction inhibitors. An infrastructure for performing pharmacokinetic, pharmacogenetic and other correlative biologic studies, integral components of the Consortium's scientific mission, utilizes the expertise of the most highly qualified investigators and laboratories within the COG. With an increasing number of investigational agents available for study, the most important consideration in the conduct of pediatric phase 1 trials will be selection of appropriate agents for evaluation. The Consortium's prioritization process utilizes data emerging from pre-clinical models in developing recommendations for prioritization of new agents to study within the Consortium. A Pre-Clinical Advisory Group of leading laboratory and clinical scientists has been formed to advise the Consortium during the prioritization process. The Consortium's infrastructure allows for flexibility in the development, design and performance of phase l and pilot studies, and is able to respond to advances in cancer therapy with the timely implementation of a scientifically sound clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (M2))
Program Officer
Smith, Malcolm M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Childhood Cancer Foundation
United States
Zip Code
London, Wendy B; Bagatell, Rochelle; Weigel, Brenda J et al. (2017) Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer 123:4914-4923
Leary, Sarah E S; Park, Julie R; Reid, Joel M et al. (2017) Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 23:6062-6069
Rheingold, Susan R; Tasian, Sarah K; Whitlock, James A et al. (2017) A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol 177:467-474
Mossé, Yael P; Voss, Stephan D; Lim, Megan S et al. (2017) Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol 35:3215-3221
Burke, Michael J; Ahern, Charlotte; Weigel, Brenda J et al. (2015) Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer 62:743-50
Voss, Stephan D; Glade-Bender, Julia; Spunt, Sheri L et al. (2015) Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer 62:45-51
Shiroishi, Mark S; Panigrahy, Ashok; Moore, Kevin R et al. (2015) Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone. Neuroradiology 57:951-6
Fouladi, Maryam; Perentesis, John P; Wagner, Lars M et al. (2015) A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 21:1558-65
Moorthy, Ganesh S; Norris, Robin E; Adamson, Peter C et al. (2014) A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 971:30-4
Weigel, Brenda; Malempati, Suman; Reid, Joel M et al. (2014) Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 61:452-6

Showing the most recent 10 out of 59 publications